ReviewMolecular and clinical oncology2025
Staphylococcal nuclease and tudor domain-containing protein 1: An emerging therapeutic target in cancer (Review).
Review in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcal nuclease and tudor domain-containing protein 1 (SND1) is an oncoprotein that is overexpressed in various types of cancer, including breast, prostate, lung, colorectal and hepatocellular carcinomas, as well as malignant gliomas, especially in cases of advanced and metastatic cancer. SND1 has a significant role in tumour development via its interactions with RNA and partner proteins. SND1 functions as a nuclease within the RNA-induced silencing complex, where small RNAs (such as siRNAs or miRNAs) bind to ribonucleoproteins to mediate RNA interference and silencing of tumour suppressor genes. Metadherin (MTDH) has been identified as an important protein partner of SND1, and the SND1-MTDH interaction has been reported to drive tumour initiation, metastasis and immune evasion in various types of cancer. Therefore, SND1 is considered as a crucial target for cancer therapy, and multiple approaches have been explored to inhibit its nuclease activity or disrupt its interaction with MTDH. In the present review, both the oncogenic functions of SND1 and therapeutic strategies that target either its binding to RNA or its interaction with MTDH are investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.